drugset / Trial / NCT05651022
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Phase 1/2
Active not recruiting
120 enrolled
Indaptus Therapeutics, Inc
Translational Drug Development · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.
Timeline
- Start
- 2023-02-28
- Primary completion
- 2027-06-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decoy20 | Other / unclassified | 3e+07 unknown | Other |
| Subject | Decoy20 | Other / unclassified | 7e+07 unknown | Other |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |